Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Applied Genetic to hold research and development day » 09:55
07/21/21
07/21
09:55
07/21/21
09:55
AGTC

Applied Genetic

$3.87 /

-0.045 (-1.15%)

Virtual Research &…

Virtual Research & Development Day will be held on July 22 at 10 am. Webcast Link

ShowHide Related Items >><<
AGTC Applied Genetic
$3.87 /

-0.045 (-1.15%)

AGTC Applied Genetic
$3.87 /

-0.045 (-1.15%)

07/09/21 Chardan
Applied Genetic coverage transferred at Chardan
06/14/21 BTIG
Applied Genetic initiated with a Buy at BTIG
04/19/21 Roth Capital
Roth Capital 'bullish' on Applied Genetic's technology, pipeline outlook
04/13/21 Roth Capital
Roth Capital sees Applied Genetic's XLRS licensing as vote of confidence
AGTC Applied Genetic
$3.87 /

-0.045 (-1.15%)

  • 28
    Jan
AGTC Applied Genetic
$3.87 /

-0.045 (-1.15%)

Conference/Events
Applied Genetic to hold research and development day » 04:55
07/21/21
07/21
04:55
07/21/21
04:55
AGTC

Applied Genetic

$3.92 /

+0.315 (+8.75%)

Virtual Research &…

Virtual Research & Development Day will be held on July 22 at 10 am. Webcast Link

ShowHide Related Items >><<
AGTC Applied Genetic
$3.92 /

+0.315 (+8.75%)

AGTC Applied Genetic
$3.92 /

+0.315 (+8.75%)

07/09/21 Chardan
Applied Genetic coverage transferred at Chardan
06/14/21 BTIG
Applied Genetic initiated with a Buy at BTIG
04/19/21 Roth Capital
Roth Capital 'bullish' on Applied Genetic's technology, pipeline outlook
04/13/21 Roth Capital
Roth Capital sees Applied Genetic's XLRS licensing as vote of confidence
AGTC Applied Genetic
$3.92 /

+0.315 (+8.75%)

  • 28
    Jan
AGTC Applied Genetic
$3.92 /

+0.315 (+8.75%)

Conference/Events
Piper Sandler biotech analysts hold an analyst/industry conference call » 09:51
07/15/21
07/15
09:51
07/15/21
09:51
RGNX

Regenxbio

$35.60 /

-0.36 (-1.00%)

, ROG

Rogers Corporation

$193.11 /

-1.44 (-0.74%)

, ADVM

Adverum Biotechnologies

$3.08 /

-0.075 (-2.38%)

, SNY

Sanofi

$51.63 /

-0.74 (-1.41%)

, JNJ

Johnson & Johnson

$169.40 /

-0.8 (-0.47%)

, BIIB

Biogen

$338.50 /

-13.56 (-3.85%)

, AGTC

Applied Genetic

$3.56 /

-0.02 (-0.56%)

, ISEE

Iveric bio

$9.34 /

-0.08 (-0.85%)

, GSGTF

Gensight Biologics

$9.90 /

+ (+0.00%)

Biotechnology Analysts…

Biotechnology Analysts Rahimi & Raymond, along with Roger A. Goldberg, MD, MBA, Ophthalmologist at Bay Area Retina Associates discuss gene therapy for ocular disease on an Analyst/Industry conference call to be held on July 15 at 10 am. Webcast Link

ShowHide Related Items >><<
SNY Sanofi
$51.63 /

-0.74 (-1.41%)

ROG Rogers Corporation
$193.11 /

-1.44 (-0.74%)

RGNX Regenxbio
$35.60 /

-0.36 (-1.00%)

JNJ Johnson & Johnson
$169.40 /

-0.8 (-0.47%)

ISEE Iveric bio
$9.34 /

-0.08 (-0.85%)

BIIB Biogen
$338.50 /

-13.56 (-3.85%)

AGTC Applied Genetic
$3.56 /

-0.02 (-0.56%)

ADVM Adverum Biotechnologies
$3.08 /

-0.075 (-2.38%)

RGNX Regenxbio
$35.60 /

-0.36 (-1.00%)

07/09/21 Chardan
Regenxbio coverage transferred at Chardan
04/29/21 Chardan
Chardan downgrades Adverum after serious adverse reaction disclosure
04/05/21 Morgan Stanley
Regenxbio AAV9 patent challenged by Passage Bio, says Morgan Stanley
02/09/21 Morgan Stanley
Sarepta denied motion to dismiss 'Wilson Wolf' case, says Morgan Stanley
ROG Rogers Corporation
$193.11 /

-1.44 (-0.74%)

06/09/21 Wolfe Research
Rogers Corporation initiated with an Outperform at Wolfe Research
05/26/21
Fly Intel: Top five analyst initiations
05/26/21 Canaccord
Canaccord starts Rogers with Buy on electrification benefits
05/26/21 Canaccord
Rogers Corporation initiated with a Buy at Canaccord
ADVM Adverum Biotechnologies
$3.08 /

-0.075 (-2.38%)

07/09/21 Chardan
Adverum Biotechnologies coverage transferred at Chardan
05/03/21 SVB Leerink
Adverum Biotechnologies downgraded to Market Perform at SVB Leerink
05/03/21 SVB Leerink
Adverum Biotechnologies downgraded to Market Perform from Outperform at SVB Leerink
SNY Sanofi
$51.63 /

-0.74 (-1.41%)

05/25/21 JPMorgan
Olema selloff brings 'compelling' entry point, says JPMorgan
04/30/21 Deutsche Bank
Sanofi price target raised to EUR 75 from EUR 70 at Deutsche Bank
04/29/21 Barclays
Sanofi price target raised to EUR 90 from EUR 85 at Barclays
04/28/21 Stifel
Protalix, Sanofi updates may signal headwinds for Avrobio, Amicus, says Stifel
JNJ Johnson & Johnson
$169.40 /

-0.8 (-0.47%)

07/08/21 Stifel
Vor Biopharma, Janssen collaboration benefits both parties, says Stifel
07/02/21 Cantor Fitzgerald
J&J vaccine shows 'strong' activist against Delta, says Cantor Fitzgerald
06/28/21 Cantor Fitzgerald
J&J opioid settlement removes share overhang, says Cantor Fitzgerald
06/22/21 JPMorgan
Opioid settlement would be best case for manufacturers, says JPMorgan
BIIB Biogen
$338.50 /

-13.56 (-3.85%)

07/13/21 Oppenheimer
Prothena price target raised to $76 from $54 at Oppenheimer
07/09/21 Stifel
FDA call for probe 'noise' for Biogen, unlikely to impact Aduhelm, says Stifel
07/08/21 Deutsche Bank
Roche upgraded to Buy from Hold at Deutsche Bank
06/28/21 RBC Capital
Biogen price target lowered to $354 from $400 at RBC Capital
AGTC Applied Genetic
$3.56 /

-0.02 (-0.56%)

07/09/21 Chardan
Applied Genetic coverage transferred at Chardan
06/14/21 BTIG
Applied Genetic initiated with a Buy at BTIG
04/19/21 Roth Capital
Roth Capital 'bullish' on Applied Genetic's technology, pipeline outlook
04/13/21 Roth Capital
Roth Capital sees Applied Genetic's XLRS licensing as vote of confidence
ISEE Iveric bio
$9.34 /

-0.08 (-0.85%)

07/06/21 Credit Suisse
Iveric bio price target raised to $16 from $14 at Credit Suisse
08/13/20 Credit Suisse
Iveric bio initiated with an Outperform at Credit Suisse
GSGTF Gensight Biologics
$9.90 /

+ (+0.00%)

07/09/21 Chardan
Gensight Biologics coverage transferred at Chardan
02/19/21 Chardan
Chardan doubles Gensight target, makes top pick for 2021
09/15/20 Chardan
Gensight Biologics price target raised to EUR 10 from EUR 8.50 at Chardan
SNY Sanofi
$51.63 /

-0.74 (-1.41%)

ROG Rogers Corporation
$193.11 /

-1.44 (-0.74%)

RGNX Regenxbio
$35.60 /

-0.36 (-1.00%)

JNJ Johnson & Johnson
$169.40 /

-0.8 (-0.47%)

ISEE Iveric bio
$9.34 /

-0.08 (-0.85%)

BIIB Biogen
$338.50 /

-13.56 (-3.85%)

AGTC Applied Genetic
$3.56 /

-0.02 (-0.56%)

ADVM Adverum Biotechnologies
$3.08 /

-0.075 (-2.38%)

  • 13
    Jul
  • 28
    Jan
  • 08
    Jan
  • 13
    Aug
SNY Sanofi
$51.63 /

-0.74 (-1.41%)

JNJ Johnson & Johnson
$169.40 /

-0.8 (-0.47%)

BIIB Biogen
$338.50 /

-13.56 (-3.85%)

SNY Sanofi
$51.63 /

-0.74 (-1.41%)

JNJ Johnson & Johnson
$169.40 /

-0.8 (-0.47%)

ISEE Iveric bio
$9.34 /

-0.08 (-0.85%)

BIIB Biogen
$338.50 /

-13.56 (-3.85%)

AGTC Applied Genetic
$3.56 /

-0.02 (-0.56%)

ADVM Adverum Biotechnologies
$3.08 /

-0.075 (-2.38%)

JNJ Johnson & Johnson
$169.40 /

-0.8 (-0.47%)

BIIB Biogen
$338.50 /

-13.56 (-3.85%)

Conference/Events
Applied Genetic to hold research and development day » 16:29
07/14/21
07/14
16:29
07/14/21
16:29
AGTC

Applied Genetic

$3.58 /

-0.17 (-4.53%)

Virtual Research &…

Virtual Research & Development Day will be held on July 22 at 10 am. Webcast Link

ShowHide Related Items >><<
AGTC Applied Genetic
$3.58 /

-0.17 (-4.53%)

AGTC Applied Genetic
$3.58 /

-0.17 (-4.53%)

07/09/21 Chardan
Applied Genetic coverage transferred at Chardan
06/14/21 BTIG
Applied Genetic initiated with a Buy at BTIG
04/19/21 Roth Capital
Roth Capital 'bullish' on Applied Genetic's technology, pipeline outlook
04/13/21 Roth Capital
Roth Capital sees Applied Genetic's XLRS licensing as vote of confidence
AGTC Applied Genetic
$3.58 /

-0.17 (-4.53%)

  • 28
    Jan
AGTC Applied Genetic
$3.58 /

-0.17 (-4.53%)

Recommendations
Applied Genetic coverage transferred at Chardan » 16:31
07/09/21
07/09
16:31
07/09/21
16:31
AGTC

Applied Genetic

$4.00 /

+0.065 (+1.65%)

Chardan transferred…

Chardan transferred coverage of Applied Genetic to analyst Geulah Livshits, who maintained a Buy rating and $8 price target on the stock.

ShowHide Related Items >><<
AGTC Applied Genetic
$4.00 /

+0.065 (+1.65%)

AGTC Applied Genetic
$4.00 /

+0.065 (+1.65%)

06/14/21 BTIG
Applied Genetic initiated with a Buy at BTIG
04/19/21 Roth Capital
Roth Capital 'bullish' on Applied Genetic's technology, pipeline outlook
04/13/21 Roth Capital
Roth Capital sees Applied Genetic's XLRS licensing as vote of confidence
03/01/21 Stifel
Applied Genetic initiated with a Buy at Stifel
AGTC Applied Genetic
$4.00 /

+0.065 (+1.65%)

  • 28
    Jan
AGTC Applied Genetic
$4.00 /

+0.065 (+1.65%)

Hot Stocks
Applied Genetic to host R&D Day on July 22 » 07:07
07/08/21
07/08
07:07
07/08/21
07:07
AGTC

Applied Genetic

$3.82 /

-0.04 (-1.04%)

Applied Genetic…

Applied Genetic Technologies Corporation announced that it will host a virtual R&D Day from 10:00 am to 1:00 pm ET on Thursday, July 22, 2021. AGTC's R&D Day will include a review of 12-month data from the highest dose groups in the ongoing Phase 1/2 clinical trials in X-linked retinitis pigmentosa, which the Company announced in May, and expanded analysis of the recently reported data from the Company's ongoing Phase 1/2 clinical trial in achromatopsia. The event also will include a discussion on light sensitivity and achromatopsia genetics, and an overview of the Company's manufacturing capabilities, including the 21,000 square foot current Good Manufacturing Practices manufacturing and quality control facility being built in Florida.

ShowHide Related Items >><<
AGTC Applied Genetic
$3.82 /

-0.04 (-1.04%)

AGTC Applied Genetic
$3.82 /

-0.04 (-1.04%)

06/14/21 BTIG
Applied Genetic initiated with a Buy at BTIG
04/19/21 Roth Capital
Roth Capital 'bullish' on Applied Genetic's technology, pipeline outlook
04/13/21 Roth Capital
Roth Capital sees Applied Genetic's XLRS licensing as vote of confidence
03/01/21 Stifel
Applied Genetic initiated with a Buy at Stifel
AGTC Applied Genetic
$3.82 /

-0.04 (-1.04%)

  • 28
    Jan
AGTC Applied Genetic
$3.82 /

-0.04 (-1.04%)

Over a month ago
Hot Stocks
Applied Genetic reports 12-month data from ongoing Phase 1/2 trial of ACHM A3 » 07:15
06/24/21
06/24
07:15
06/24/21
07:15
AGTC

Applied Genetic

$4.17 /

+0.02 (+0.48%)

Applied Genetic…

Applied Genetic Technologies reported 12-month data from its ongoing achromatopsia Phase 1/2 clinical trials. The path forward for ACHM A3 will be determined after additional pediatric patient data and pre-clinical studies are available and can be evaluated. 12-month data for ACHM A3 are available for 20 patients, including 16 adults and 4 pediatric patients. The results at this time point do not show consistent evidence of ACHM A3 candidate biologic activity, although we believe that the patient-reported anecdotes continue to be encouraging. In contrast with patients in the B3 trial, the majority of whom have mutations that results in the complete absence of B3 protein, the majority of A3 patients have mutations that result in the production of non-functional protein. The results observed to date in the Phase 1/2 ACHM trials suggest that the presence of these non-functional proteins may interfere with the activity of the vector expressed ACHM A3 protein.

ShowHide Related Items >><<
AGTC Applied Genetic
$4.17 /

+0.02 (+0.48%)

AGTC Applied Genetic
$4.17 /

+0.02 (+0.48%)

06/14/21 BTIG
Applied Genetic initiated with a Buy at BTIG
04/19/21 Roth Capital
Roth Capital 'bullish' on Applied Genetic's technology, pipeline outlook
04/13/21 Roth Capital
Roth Capital sees Applied Genetic's XLRS licensing as vote of confidence
03/01/21 Stifel
Applied Genetic initiated with a Buy at Stifel
AGTC Applied Genetic
$4.17 /

+0.02 (+0.48%)

  • 28
    Jan
AGTC Applied Genetic
$4.17 /

+0.02 (+0.48%)

Hot Stocks
Applied Genetic reports 12-month data from ongoing Phase 1/2 trial of ACHM B3 » 07:15
06/24/21
06/24
07:15
06/24/21
07:15
AGTC

Applied Genetic

$4.17 /

+0.02 (+0.48%)

Applied Genetic reported…

Applied Genetic reported 12-month data from its ongoing achromatopsia Phase 1/2 clinical trial. For its ACHM B3 candidate, results demonstrate biologic activity based on improvements in visual sensitivity in the treated area measured by static perimetry and light discomfort measured by the Ocular Photosensitivity Analyzer and are supported by anecdotal patient reports. Based on these data, AGTC intends to advance the ACHM B3 trial to the next stage of clinical development. 12-month data, which are available for 25 patients, consisting of 21 adult and 4 pediatric patients, show continued improvements on perimetry for higher dose and younger patients and include positive patient anecdotes. Improvements in retinal sensitivity as measured by static perimetry were seen in the treated eye compared with the untreated eye in four of 11 patients from the high-dose and pediatric cohorts. Improvements in light discomfort as measured by OPA, were also observed in six of these 11 patients. Improvements in light discomfort also were observed in the untreated eye of these patients, which we believe may suggest possible cortical adaptation within the brain. There is no evidence that this observation is due to the presence of the ACHM B3 vector in the untreated eye. Based on these data, AGTC plans to advance its ACHM B3 program to the next stage of clinical development. Toward this end, the Company is drafting an End-of-Phase 2 briefing packet to submit to the U.S. Food and Drug Administration, developing assays for pivotal ready testing, and planning production of clinical trial material. AGTC believes it has a best-in-class ACHM B3 product candidate that may provide significant benefit to patients. The Company expects to report 3-month data from younger pediatric patients in both the ACHM B3 and ACHM A3 trials in the fourth quarter of 2021.

ShowHide Related Items >><<
AGTC Applied Genetic
$4.17 /

+0.02 (+0.48%)

AGTC Applied Genetic
$4.17 /

+0.02 (+0.48%)

06/14/21 BTIG
Applied Genetic initiated with a Buy at BTIG
04/19/21 Roth Capital
Roth Capital 'bullish' on Applied Genetic's technology, pipeline outlook
04/13/21 Roth Capital
Roth Capital sees Applied Genetic's XLRS licensing as vote of confidence
03/01/21 Stifel
Applied Genetic initiated with a Buy at Stifel
AGTC Applied Genetic
$4.17 /

+0.02 (+0.48%)

  • 28
    Jan
AGTC Applied Genetic
$4.17 /

+0.02 (+0.48%)

Initiation
Applied Genetic initiated with a Buy at BTIG » 16:32
06/14/21
06/14
16:32
06/14/21
16:32
AGTC

Applied Genetic

$4.29 /

+0.035 (+0.82%)

BTIG analyst Yun Zhong…

BTIG analyst Yun Zhong initiated coverage of Applied Genetic with a Buy rating and $11 price target as part of a broader research note urging biotech investors to "start with gene therapy". The analyst likes the company's strong focus on inherited retinal disorders, which are an "ideal target" for AAV gene therapy. Zhong adds that Applied Genetic offers highly favorable risk-reward with the stock trading slightly above 52-week low.

ShowHide Related Items >><<
AGTC Applied Genetic
$4.29 /

+0.035 (+0.82%)

AGTC Applied Genetic
$4.29 /

+0.035 (+0.82%)

04/19/21 Roth Capital
Roth Capital 'bullish' on Applied Genetic's technology, pipeline outlook
04/13/21 Roth Capital
Roth Capital sees Applied Genetic's XLRS licensing as vote of confidence
03/01/21 Stifel
Applied Genetic initiated with a Buy at Stifel
02/02/21 H.C. Wainwright
Applied Genetic price target raised to $24 from $18 at H.C. Wainwright
AGTC Applied Genetic
$4.29 /

+0.035 (+0.82%)

  • 28
    Jan
AGTC Applied Genetic
$4.29 /

+0.035 (+0.82%)

Hot Stocks
Editas Medicine announces new Chief Regulatory Officer, Chief Scientific Officer » 09:24
06/14/21
06/14
09:24
06/14/21
09:24
EDIT

Editas Medicine

$37.45 /

+0.58 (+1.57%)

, AGTC

Applied Genetic

$4.25 /

-0.02 (-0.47%)

Editas Medicine (EDIT)…

Editas Medicine (EDIT) announced that it named Chi Li, Ph.D., MBA, RAC, as the company's Senior Vice President and Chief Regulatory Officer, effective immediately. Li will lead regulatory affairs strategy and activities related to Editas Medicine's drug development programs. Additionally, as previously announced, Dr. Mark Shearman, Ph.D., joined the company as Executive Vice President and Chief Scientific Officer. Shearman joins Editas Medicine from Applied Genetic Technologies Corporation (AGTC), where he served as Chief Scientific Officer and was responsible for leading the company's product candidate selection process, pre-clinical and translational research, and long-term research and development planning. Li joins Editas Medicine from Celularity where he served as Chief Regulatory Officer.

ShowHide Related Items >><<
EDIT Editas Medicine
$37.45 /

+0.58 (+1.57%)

AGTC Applied Genetic
$4.25 /

-0.02 (-0.47%)

EDIT Editas Medicine
$37.45 /

+0.58 (+1.57%)

06/03/21 Baird
Editas Medicine assumed with an Outperform at Baird
05/05/21 Chardan
Editas may be positioned for some second half rebound, says Chardan
05/03/21 RBC Capital
Editas Medicine initiated with a Sector Perform at RBC Capital
04/16/21
Fly Intel: Top five analyst initiations
AGTC Applied Genetic
$4.25 /

-0.02 (-0.47%)

04/19/21 Roth Capital
Roth Capital 'bullish' on Applied Genetic's technology, pipeline outlook
04/13/21 Roth Capital
Roth Capital sees Applied Genetic's XLRS licensing as vote of confidence
03/01/21 Stifel
Applied Genetic initiated with a Buy at Stifel
02/02/21 H.C. Wainwright
Applied Genetic price target raised to $24 from $18 at H.C. Wainwright
EDIT Editas Medicine
$37.45 /

+0.58 (+1.57%)

AGTC Applied Genetic
$4.25 /

-0.02 (-0.47%)

  • 28
    Jan
  • 21
    Jan
  • 24
    Jun
EDIT Editas Medicine
$37.45 /

+0.58 (+1.57%)

AGTC Applied Genetic
$4.25 /

-0.02 (-0.47%)

EDIT Editas Medicine
$37.45 /

+0.58 (+1.57%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.